San Diego-based Replicate Bioscience, which is looking to use self-replicating RNA (srRNA) to treat cancer, autoimmune, inflammatory disorders and other diseases, has raised $40M in its Series A funding. The funding was led by life sciences venture capital investor ATP. According to the companies, Replicate will use that funding to advance multiple novel srRNA programs into clinical development. Replicate is led by CEO Nathaniel Wang, Ph.D. The company's scientific founders also include Andrew Geall, Ph.D. (previously at Synthetic Genomics and at Novartis Vaccines and Diagnostics) and Herbert Kim Lyerly, M.D., and Zachary Hartman, Ph.D., both professors of cancer research and immunology at Duke University.